This clinical trial is focused on studying treatments for patients who are immunocompromised and experiencing acute respiratory failure of unknown origin. Being immunocompromised means that a person’s immune system is weakened, which can happen due to conditions like cancer or after receiving an organ transplant. The study will explore the effects of using steroids and/or antifungal medications to help these patients. Specifically, the trial will use a steroid called METHYLPREDNISOLONE and an antifungal medication called CRESEMBA (also known as isavuconazonium sulfate).

The purpose of the study is to see if these treatments can reduce the risk of death within 90 days for patients with acute respiratory failure. Participants in the study will receive either the medications or a placebo, which is a substance with no active ingredients, for up to 14 days or until they are discharged from the intensive care unit (ICU). The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor various outcomes, including survival rates at different time points, the occurrence of infections, and the overall quality of life of the participants. The goal is to gather information that could lead to better treatment strategies for immunocompromised patients facing severe respiratory issues.